Hand-Held Light Technology Inactivates Coronavirus Variants

North Carolina-based EmitBio Inc. announced new evidence demonstrating its proprietary light technology could inactivate variants of the coronavirus that causes COVID-19, including the highly infectious United Kingdom and South Africa variants.

These findings published on March 10, 2021, indicate important effectiveness against potentially more transmissible mutations of COVID-19.

EmitBio™ has developed a novel, hand-held treatment device that directs energy into the upper respiratory tract with 100% of the dose available in the area of need, thereby avoiding the possible side effects of systemic treatments. This non-FDA authorized device has been designed as an at-home treatment for mild-tomoderate COVID-19 in adults testing positive for SARS-CoV-2.

Neal Hunter, Executive Chairman of EmitBio, commented in a press release, “We have clearly demonstrated that EmitBio treatment technology is mutation resistant and resilient. This is an important weapon in the global fight against an enemy that keeps evolving.”

The company recently reported results from a clinical trial with the investigational treatment device, which showed a 99.9% reduction in viral load in adults with COVID-19. The clinical trial results, along with the results from a Phase I safety study in healthy volunteers, have been submitted as part of a comprehensive package to the U.S. FDA requesting Emergency Use Authorization.

EmitBio Inc. is a life science company using the precise delivery of light to stimulate, heal and protect the body.